The choroid plexus is a plexus of cells that produces the cerebrospinal fluid in the ventricles of the brain.
The published application recognises a significant number of claims relating to Living Cell’s lead product, NTCELL.
NTCELL is a microcapsule which functions as a biological factory, producing factors to promote central nervous system growth and repair disease-induced nerve degeneration.
The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease has met the primary endpoint of safety and reversed progression of the disease two years after implant.
Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL and define any placebo component of the response. This trial commenced in March 2016.
If the trial is successful, the company will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease.
In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Alzheimer’s and amyotrophic lateral sclerosis (ALS).
Living Cell’s share price has increased by about 71% in the past one year, last trading at $0.084.
Story by ProactiveInvestors